ID   MTHR_HUMAN              Reviewed;         656 AA.
AC   P42898; B2R7A6; Q5SNW6; Q5SNW9; Q7Z6M6; Q8IU73; Q9UQR2;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   07-DEC-2004, sequence version 3.
DT   10-MAY-2017, entry version 170.
DE   RecName: Full=Methylenetetrahydrofolate reductase {ECO:0000305};
DE            EC=1.5.1.20 {ECO:0000269|PubMed:25736335};
GN   Name=MTHFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Rozen R., Goyette P.;
RT   "cDNA for human methylenetetrahydrofolate reductase.";
RL   Patent number WO9533054, 07-DEC-1995.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9680386; DOI=10.1007/s003359900838;
RA   Goyette P., Pai A., Milos R., Frosst P., Tran P., Chen Z., Chan M.,
RA   Rozen R.;
RT   "Gene structure of human and mouse methylenetetrahydrofolate reductase
RT   (MTHFR).";
RL   Mamm. Genome 9:652-656(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Homberger A., Linnebank M., Winter C., Rapp B., Koch H.G.;
RT   "Revised translation initiation site of the human
RT   methylenetetrahydrofolate reductase (MTHFR).";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   VAL-222.
RC   TISSUE=Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-68; VAL-222;
RP   ARG-422; ALA-429; CYS-519; GLN-594 AND MET-653.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   GLN-594.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-415 (ISOFORM 1), AND VARIANT
RP   HOMOCYSTINURIA GLN-157.
RC   TISSUE=Liver;
RX   PubMed=7920641; DOI=10.1038/ng0694-195;
RA   Goyette P., Sumner J.S., Milos R., Duncan A.M.V., Rosenblatt D.S.,
RA   Matthews R.G., Rozen R.;
RT   "Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping
RT   and mutation identification.";
RL   Nat. Genet. 7:195-200(1994).
RN   [10]
RP   ERRATUM.
RX   PubMed=7951330;
RA   Goyette P., Sumner J.S., Milos R., Duncan A.M.V., Rosenblatt D.S.,
RA   Matthews R.G., Rozen R.;
RL   Nat. Genet. 7:551-551(1994).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-71 (ISOFORM 2), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=12370778; DOI=10.1007/s00335-002-2167-6;
RA   Tran P., Leclerc D., Chan M., Pai A., Hiou-Tim F., Wu Q., Goyette P.,
RA   Artigas C., Milos R., Rozen R.;
RT   "Multiple transcription start sites and alternative splicing in the
RT   methylenetetrahydrofolate reductase gene result in two enzyme
RT   isoforms.";
RL   Mamm. Genome 13:483-492(2002).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   VARIANTS MTHFRD GLN-52; MET-227; LEU-251; CYS-325; CYS-335 AND
RP   CYS-357, AND SEQUENCE REVISION TO 177.
RX   PubMed=7726158;
RA   Goyette P., Frosst P., Rosenblatt D.S., Rozen R.;
RT   "Seven novel mutations in the methylenetetrahydrofolate reductase gene
RT   and genotype/phenotype correlations in severe
RT   methylenetetrahydrofolate reductase deficiency.";
RL   Am. J. Hum. Genet. 56:1052-1059(1995).
RN   [14]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, AND VARIANT VAL-222.
RX   PubMed=7564788; DOI=10.1016/S0140-6736(95)91743-8;
RA   van der Put N.M.J., Steegers-Theunissen R.P.M., Frosst P.,
RA   Trijbels F.J.M., Eskes T.K.A.B., van den Heuvel L.P., Mariman E.C.M.,
RA   den Heyer M., Rozen R., Blom H.J.;
RT   "Mutated methylenetetrahydrofolate reductase as a risk factor for
RT   spina bifida.";
RL   Lancet 346:1070-1071(1995).
RN   [15]
RP   VARIANT VAL-222.
RX   PubMed=7647779; DOI=10.1038/ng0595-111;
RA   Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A.,
RA   Matthews R.G., Boers G.J.H., den Heijer M., Kluijtmans L.A.J.,
RA   van den Heuvel L.P., Rozen R.;
RT   "A candidate genetic risk factor for vascular disease: a common
RT   mutation in methylenetetrahydrofolate reductase.";
RL   Nat. Genet. 10:111-113(1995).
RN   [16]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, AND VARIANT VAL-222.
RX   PubMed=8826441;
RX   DOI=10.1002/(SICI)1096-8628(19960628)63:4<610::AID-AJMG15>3.0.CO;2-L;
RA   Ou C.Y., Stevenson R.E., Brown V.K., Schwartz C.E., Allen W.P.,
RA   Khoury M.J., Rozen R., Oakley G.P. Jr., Adams M.J. Jr.;
RT   "5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a
RT   risk factor for neural tube defects.";
RL   Am. J. Med. Genet. 63:610-614(1996).
RN   [17]
RP   VARIANTS MTHFRD PRO-51; PRO-323 AND CYS-377.
RX   PubMed=8940272;
RA   Goyette P., Christensen B., Rosenblatt D.S., Rozen R.;
RT   "Severe and mild mutations in cis for the methylenetetrahydrofolate
RT   reductase (MTHFR) gene, and description of five novel mutations in
RT   MTHFR.";
RL   Am. J. Hum. Genet. 59:1268-1275(1996).
RN   [18]
RP   INVERSE ASSOCIATION OF VARIANT VAL-222 WITH COLORECTAL CANCER.
RX   PubMed=8895734;
RA   Chen J., Giovannucci E., Kelsey K., Rimm E.B., Stampfer M.J.,
RA   Colditz G.A., Spiegelman D., Willett W.C., Hunter D.J.;
RT   "A methylenetetrahydrofolate reductase polymorphism and the risk of
RT   colorectal cancer.";
RL   Cancer Res. 56:4862-4864(1996).
RN   [19]
RP   VARIANT VAL-222.
RX   PubMed=9545406; DOI=10.1086/301836;
RA   Schneider J.A., Rees D.C., Liu Y.-T., Clegg J.B.;
RT   "Worldwide distribution of a common methylenetetrahydrofolate
RT   reductase mutation.";
RL   Am. J. Hum. Genet. 62:1258-1260(1998).
RN   [20]
RP   VARIANT ALA-429.
RX   PubMed=9545395; DOI=10.1086/301825;
RA   van der Put N.M.J., Gabreels F., Stevens E.M.B., Smeitink J.A.M.,
RA   Trijbels F.J.M., Eskes T.K.A.B., van den Heuvel L.P., Blom H.J.;
RT   "A second mutation in the methylenetetrahydrofolate reductase gene: an
RT   additional risk factor for neural-tube defects?";
RL   Am. J. Hum. Genet. 62:1044-1051(1998).
RN   [21]
RP   VARIANTS MTHFRD SER-324 AND GLY-339.
RX   PubMed=9781030; DOI=10.1038/sj.ejhg.5200182;
RA   Kluijtmans L.A.J., Wendel U., Stevens E.M.B., van den Heuvel L.P.W.J.,
RA   Trijbels F.J.M., Blom H.J.;
RT   "Identification of four novel mutations in severe
RT   methylenetetrahydrofolate reductase deficiency.";
RL   Eur. J. Hum. Genet. 6:257-265(1998).
RN   [22]
RP   VARIANT ALA-429.
RX   PubMed=9719624; DOI=10.1006/mgme.1998.2714;
RA   Weisberg I., Tran P., Christiensen B., Sibani S., Rozen R.;
RT   "A second genetic polymorphism in methylenetetrahydrofolate reductase
RT   (MTHFR) associated with decreased enzyme activity.";
RL   Mol. Genet. Metab. 64:169-172(1998).
RN   [23]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, AND VARIANT VAL-222.
RX   PubMed=10323741;
RX   DOI=10.1002/(SICI)1096-8628(19990521)84:2<151::AID-AJMG12>3.0.CO;2-T;
RA   Christensen B., Arbour L., Tran P., Leclerc D., Sabbaghian N.,
RA   Platt R., Gilfix B.M., Rosenblatt D.S., Gravel R.A., Forbes P.,
RA   Rozen R.;
RT   "Genetic polymorphisms in methylenetetrahydrofolate reductase and
RT   methionine synthase, folate levels in red blood cells, and risk of
RT   neural tube defects.";
RL   Am. J. Med. Genet. 84:151-157(1999).
RN   [24]
RP   VARIANTS VAL-222 AND ALA-429, AND ASSOCIATION WITH SUSCEPTIBILITY TO
RP   ACUTE LEUKEMIA.
RX   PubMed=10536004; DOI=10.1073/pnas.96.22.12810;
RA   Skibola C.F., Smith M.T., Kane E., Roman E., Rollinson S.,
RA   Cartwright R.A., Morgan G.;
RT   "Polymorphisms in the methylenetetrahydrofolate reductase gene are
RT   associated with susceptibility to acute leukemia in adults.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:12810-12815(1999).
RN   [25]
RP   VARIANTS MTHFRD ASP-387; LEU-572 AND LYS-586.
RX   PubMed=10679944;
RX   DOI=10.1002/(SICI)1098-1004(200003)15:3<280::AID-HUMU9>3.0.CO;2-I;
RA   Sibani S., Christensen B., O'Ferrall E., Saadi I., Hiou-Tim F.,
RA   Rosenblatt D.S., Rozen R.;
RT   "Characterization of six novel mutations in the
RT   methylenetetrahydrofolate reductase (MTHFR) gene in patients with
RT   homocystinuria.";
RL   Hum. Mutat. 15:280-287(2000).
RN   [26]
RP   ASSOCIATION OF VARIANT VAL-222 WITH SUSCEPTIBILITY TO ISCHSTR.
RX   PubMed=15534175; DOI=10.1001/archneur.61.11.1652;
RA   Casas J.P., Hingorani A.D., Bautista L.E., Sharma P.;
RT   "Meta-analysis of genetic studies in ischemic stroke: thirty-two genes
RT   involving approximately 18,000 cases and 58,000 controls.";
RL   Arch. Neurol. 61:1652-1661(2004).
RN   [27]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-470.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [28]
RP   VARIANTS MTHFRD LEU-218; SER-435 AND GLY-574, CHARACTERIZATION OF
RP   VARIANT MTHFRD LEU-218, CHARACTERIZATION OF VARIANT VAL-222, AND
RP   COFACTOR.
RX   PubMed=20236116; DOI=10.1111/j.1399-0004.2010.01391.x;
RA   Urreizti R., Moya-Garcia A.A., Pino-Angeles A., Cozar M.,
RA   Langkilde A., Fanhoe U., Esteves C., Arribas J., Vilaseca M.A.,
RA   Perez-Duenas B., Pineda M., Gonzalez V., Artuch R., Baldellou A.,
RA   Vilarinho L., Fowler B., Ribes A., Sanchez-Jimenez F., Grinberg D.,
RA   Balcells S.;
RT   "Molecular characterization of five patients with homocystinuria due
RT   to severe methylenetetrahydrofolate reductase deficiency.";
RL   Clin. Genet. 78:441-448(2010).
RN   [29]
RP   VARIANTS MTHFRD GLN-46; TRP-46; GLN-52; SER-59; GLY-68; TRP-82;
RP   THR-113; TYR-127; ASN-129; ARG-130; PRO-147; VAL-149; MET-153;
RP   GLN-157; THR-175; GLN-183; VAL-195; ASP-196; LYS-215 DEL; LEU-225;
RP   ILE-226 DEL; PHE-253; SER-254; VAL-255; ASN-256; VAL-257; HIS-335;
RP   THR-338; GLY-339; SER-348; TYR-354; HIS-363; GLU-372; CYS-377;
RP   HIS-377; ASP-387; SER-421; ASP-506; PHE-536; LEU-572; GLY-574;
RP   GLY-575; PRO-598 AND PRO-628, CHARACTERIZATION OF VARIANTS MTHFRD
RP   GLN-46; TRP-46; GLN-52; SER-59; GLY-68; TRP-82; THR-113; TYR-127;
RP   ASN-129; ARG-130; PRO-147; VAL-149; MET-153; GLN-157; THR-175;
RP   GLN-183; VAL-195; ASP-196; LYS-215 DEL; LEU-225; ILE-226 DEL; PHE-253;
RP   SER-254; VAL-255; ASN-256; VAL-257; HIS-335; THR-338; GLY-339;
RP   SER-348; TYR-354; HIS-363; GLU-372; CYS-377; HIS-377; ASP-387;
RP   SER-421; ASP-506; PHE-536; LEU-572; GLY-574; GLY-575; PRO-598 AND
RP   PRO-628, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=25736335; DOI=10.1002/humu.22779;
RA   Burda P., Schaefer A., Suormala T., Rummel T., Buerer C.,
RA   Heuberger D., Frapolli M., Giunta C., Sokolova J., Vlaskova H.,
RA   Kozich V., Koch H.G., Fowler B., Froese D.S., Baumgartner M.R.;
RT   "Insights into severe 5,10-methylenetetrahydrofolate reductase
RT   deficiency: molecular genetic and enzymatic characterization of 76
RT   patients.";
RL   Hum. Mutat. 36:611-621(2015).
CC   -!- FUNCTION: Catalyzes the conversion of 5,10-
CC       methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-
CC       substrate for homocysteine remethylation to methionine.
CC       {ECO:0000269|PubMed:25736335}.
CC   -!- CATALYTIC ACTIVITY: 5-methyltetrahydrofolate + NAD(P)(+) = 5,10-
CC       methylenetetrahydrofolate + NAD(P)H.
CC       {ECO:0000269|PubMed:25736335}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:20236116};
CC   -!- ENZYME REGULATION: Allosterically regulated by S-
CC       adenosylmethionine.
CC   -!- PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion.
CC   -!- SUBUNIT: Homodimer.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P42898-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P42898-2; Sequence=VSP_053744;
CC   -!- POLYMORPHISM: Genetic variation in MTHFR influences susceptibility
CC       to occlusive vascular disease, neural tube defects (NTD), colon
CC       cancer and acute leukemia.
CC   -!- DISEASE: Methylenetetrahydrofolate reductase deficiency (MTHFRD)
CC       [MIM:236250]: Autosomal recessive disorder with a wide range of
CC       features including homocysteinuria, homocysteinemia [MIM:603174],
CC       developmental delay, severe mental retardation, perinatal death,
CC       psychiatric disturbances, and later-onset neurodegenerative
CC       disorders. {ECO:0000269|PubMed:10679944,
CC       ECO:0000269|PubMed:20236116, ECO:0000269|PubMed:25736335,
CC       ECO:0000269|PubMed:7726158, ECO:0000269|PubMed:8940272,
CC       ECO:0000269|PubMed:9781030}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Ischemic stroke (ISCHSTR) [MIM:601367]: A stroke is an
CC       acute neurologic event leading to death of neural tissue of the
CC       brain and resulting in loss of motor, sensory and/or cognitive
CC       function. Ischemic strokes, resulting from vascular occlusion, is
CC       considered to be a highly complex disease consisting of a group of
CC       heterogeneous disorders with multiple genetic and environmental
CC       risk factors. {ECO:0000269|PubMed:15534175}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Neural tube defects, folate-sensitive (NTDFS)
CC       [MIM:601634]: The most common NTDs are open spina bifida
CC       (myelomeningocele) and anencephaly. {ECO:0000269|PubMed:10323741,
CC       ECO:0000269|PubMed:7564788, ECO:0000269|PubMed:8826441}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the methylenetetrahydrofolate reductase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MTHFRID41448ch1p36.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mthfr/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=MTHFR";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Methylenetetrahydrofolate
CC       reductase entry;
CC       URL="https://en.wikipedia.org/wiki/Methylenetetrahydrofolate_reductase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U09806; AAA74440.2; -; mRNA.
DR   EMBL; AF105987; AAD17965.1; -; Genomic_DNA.
DR   EMBL; AF105977; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105978; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105979; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105980; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105981; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105982; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105983; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105984; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105985; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AF105986; AAD17965.1; JOINED; Genomic_DNA.
DR   EMBL; AJ237672; CAB41971.1; -; mRNA.
DR   EMBL; AK312907; BAG35753.1; -; mRNA.
DR   EMBL; AY338232; AAP88033.1; -; Genomic_DNA.
DR   EMBL; AL953897; CAI15885.1; -; Genomic_DNA.
DR   EMBL; CH471130; EAW71709.1; -; Genomic_DNA.
DR   EMBL; BC053509; AAH53509.1; -; mRNA.
DR   EMBL; AY046562; AAL17648.1; -; mRNA.
DR   EMBL; AF398930; AAN40865.1; -; Genomic_DNA.
DR   CCDS; CCDS137.1; -. [P42898-1]
DR   CCDS; CCDS81262.1; -. [P42898-2]
DR   PIR; S46454; S46454.
DR   RefSeq; NP_001317287.1; NM_001330358.1. [P42898-2]
DR   RefSeq; NP_005948.3; NM_005957.4. [P42898-1]
DR   RefSeq; XP_005263517.1; XM_005263460.4. [P42898-1]
DR   RefSeq; XP_005263519.1; XM_005263462.4. [P42898-1]
DR   UniGene; Hs.214142; -.
DR   UniGene; Hs.737916; -.
DR   ProteinModelPortal; P42898; -.
DR   SMR; P42898; -.
DR   BioGrid; 110624; 20.
DR   IntAct; P42898; 2.
DR   STRING; 9606.ENSP00000365775; -.
DR   DrugBank; DB00542; Benazepril.
DR   DrugBank; DB00115; Cyanocobalamin.
DR   DrugBank; DB00544; Fluorouracil.
DR   DrugBank; DB00158; Folic Acid.
DR   DrugBank; DB00134; L-Methionine.
DR   DrugBank; DB00170; Menadione.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB00140; Riboflavin.
DR   DrugBank; DB00116; Tetrahydrofolic acid.
DR   iPTMnet; P42898; -.
DR   PhosphoSitePlus; P42898; -.
DR   BioMuta; MTHFR; -.
DR   DMDM; 56405339; -.
DR   EPD; P42898; -.
DR   MaxQB; P42898; -.
DR   PaxDb; P42898; -.
DR   PeptideAtlas; P42898; -.
DR   PRIDE; P42898; -.
DR   Ensembl; ENST00000376583; ENSP00000365767; ENSG00000177000. [P42898-2]
DR   Ensembl; ENST00000376585; ENSP00000365770; ENSG00000177000. [P42898-2]
DR   Ensembl; ENST00000376590; ENSP00000365775; ENSG00000177000. [P42898-1]
DR   Ensembl; ENST00000376592; ENSP00000365777; ENSG00000177000. [P42898-1]
DR   GeneID; 4524; -.
DR   KEGG; hsa:4524; -.
DR   UCSC; uc001atc.3; human. [P42898-1]
DR   CTD; 4524; -.
DR   DisGeNET; 4524; -.
DR   GeneCards; MTHFR; -.
DR   HGNC; HGNC:7436; MTHFR.
DR   HPA; HPA063389; -.
DR   MalaCards; MTHFR; -.
DR   MIM; 236250; phenotype.
DR   MIM; 601367; phenotype.
DR   MIM; 601634; phenotype.
DR   MIM; 603174; phenotype.
DR   MIM; 607093; gene.
DR   neXtProt; NX_P42898; -.
DR   OpenTargets; ENSG00000177000; -.
DR   Orphanet; 268392; Cervical spina bifida aperta.
DR   Orphanet; 268762; Cervical spina bifida cystica.
DR   Orphanet; 268397; Cervicothoracic spina bifida aperta.
DR   Orphanet; 268766; Cervicothoracic spina bifida cystica.
DR   Orphanet; 395; Homocystinuria due to methylene tetrahydrofolate reductase deficiency.
DR   Orphanet; 1048; Isolated anencephaly/exencephaly.
DR   Orphanet; 268388; Lumbosacral spina bifida aperta.
DR   Orphanet; 268758; Lumbosacral spina bifida cystica.
DR   Orphanet; 413690; Methotrexate toxicity or dose selection.
DR   Orphanet; 64738; Non rare thrombophilia.
DR   Orphanet; 268384; Thoracolumbosacral spina bifida aperta.
DR   Orphanet; 268752; Thoracolumbosacral spina bifida cystica.
DR   Orphanet; 268377; Total spina bifida aperta.
DR   Orphanet; 268748; Total spina bifida cystica.
DR   Orphanet; 268740; Upper thoracic spina bifida aperta.
DR   Orphanet; 268770; Upper thoracic spina bifida cystica.
DR   PharmGKB; PA245; -.
DR   eggNOG; KOG0564; Eukaryota.
DR   eggNOG; COG0685; LUCA.
DR   GeneTree; ENSGT00390000012490; -.
DR   HOGENOM; HOG000246234; -.
DR   HOVERGEN; HBG006414; -.
DR   InParanoid; P42898; -.
DR   KO; K00297; -.
DR   OMA; VVGWGPS; -.
DR   OrthoDB; EOG091G0YQK; -.
DR   PhylomeDB; P42898; -.
DR   TreeFam; TF105665; -.
DR   BRENDA; 1.5.1.20; 2681.
DR   Reactome; R-HSA-196757; Metabolism of folate and pterines.
DR   SABIO-RK; P42898; -.
DR   UniPathway; UPA00193; -.
DR   ChiTaRS; MTHFR; human.
DR   GeneWiki; Methylenetetrahydrofolate_reductase; -.
DR   GenomeRNAi; 4524; -.
DR   PRO; PR:P42898; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000177000; -.
DR   CleanEx; HS_MTHFR; -.
DR   ExpressionAtlas; P42898; baseline and differential.
DR   Genevisible; P42898; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IDA:BHF-UCL.
DR   GO; GO:0004489; F:methylenetetrahydrofolate reductase (NAD(P)H) activity; IDA:BHF-UCL.
DR   GO; GO:0072341; F:modified amino acid binding; IDA:UniProtKB.
DR   GO; GO:0050661; F:NADP binding; IEA:Ensembl.
DR   GO; GO:0032403; F:protein complex binding; IPI:BHF-UCL.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0006520; P:cellular amino acid metabolic process; TAS:ProtInc.
DR   GO; GO:0046655; P:folic acid metabolic process; TAS:Reactome.
DR   GO; GO:0070829; P:heterochromatin maintenance; IDA:BHF-UCL.
DR   GO; GO:0050667; P:homocysteine metabolic process; IDA:UniProtKB.
DR   GO; GO:0006555; P:methionine metabolic process; IGI:BHF-UCL.
DR   GO; GO:0031060; P:regulation of histone methylation; IDA:BHF-UCL.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0051593; P:response to folic acid; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0033274; P:response to vitamin B2; IEA:Ensembl.
DR   GO; GO:0046500; P:S-adenosylmethionine metabolic process; IEA:Ensembl.
DR   GO; GO:0035999; P:tetrahydrofolate interconversion; IDA:BHF-UCL.
DR   CDD; cd00537; MTHFR; 1.
DR   Gene3D; 3.20.20.220; -; 1.
DR   InterPro; IPR029041; FAD-linked_oxidoreductase-like.
DR   InterPro; IPR004621; Fadh2_euk.
DR   InterPro; IPR003171; Mehydrof_redctse.
DR   Pfam; PF02219; MTHFR; 1.
DR   SUPFAM; SSF51730; SSF51730; 1.
DR   TIGRFAMs; TIGR00677; fadh2_euk; 1.
PE   1: Evidence at protein level;
KW   Allosteric enzyme; Alternative splicing; Complete proteome;
KW   Disease mutation; FAD; Flavoprotein; NADP; Oxidoreductase;
KW   Polymorphism; Reference proteome.
FT   CHAIN         1    656       Methylenetetrahydrofolate reductase.
FT                                /FTId=PRO_0000190245.
FT   NP_BIND      63     68       NAD. {ECO:0000250}.
FT   NP_BIND      94     95       NAD and FAD. {ECO:0000250}.
FT   NP_BIND     157    159       FAD. {ECO:0000250}.
FT   NP_BIND     174    175       FAD. {ECO:0000250}.
FT   NP_BIND     201    204       FAD. {ECO:0000250}.
FT   ACT_SITE     63     63       Proton donor/acceptor. {ECO:0000250}.
FT   BINDING     127    127       FAD. {ECO:0000250}.
FT   BINDING     159    159       Substrate. {ECO:0000250}.
FT   BINDING     197    197       FAD. {ECO:0000250}.
FT   BINDING     210    210       FAD. {ECO:0000250}.
FT   BINDING     217    217       FAD. {ECO:0000250}.
FT   BINDING     228    228       Substrate. {ECO:0000250}.
FT   BINDING     321    321       Substrate. {ECO:0000250}.
FT   BINDING     325    325       Substrate. {ECO:0000250}.
FT   VAR_SEQ       1      1       M -> MDHRKARVLPAGHYCPSLGIWASQVGSVRSSVPPSI
FT                                SRNPAM (in isoform 2).
FT                                {ECO:0000303|PubMed:12370778}.
FT                                /FTId=VSP_053744.
FT   VARIANT      46     46       R -> Q (in MTHFRD; reduces
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs776483190).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074111.
FT   VARIANT      46     46       R -> W (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs138189536).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074112.
FT   VARIANT      51     51       R -> P (in MTHFRD; dbSNP:rs201618781).
FT                                {ECO:0000269|PubMed:8940272}.
FT                                /FTId=VAR_009530.
FT   VARIANT      52     52       R -> Q (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs754980119).
FT                                {ECO:0000269|PubMed:25736335,
FT                                ECO:0000269|PubMed:7726158}.
FT                                /FTId=VAR_004319.
FT   VARIANT      59     59       W -> S (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs786204007).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074113.
FT   VARIANT      68     68       R -> G (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs763539350).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074114.
FT   VARIANT      68     68       R -> Q (in dbSNP:rs2066472).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014881.
FT   VARIANT      82     82       R -> W (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs786204009).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074115.
FT   VARIANT     113    113       A -> T (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs147257424).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074116.
FT   VARIANT     127    127       H -> Y (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs769381688).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074117.
FT   VARIANT     129    129       T -> N (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074118.
FT   VARIANT     130    130       C -> R (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs786204012).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074119.
FT   VARIANT     147    147       Q -> P (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs786204013).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074120.
FT   VARIANT     149    149       G -> V (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity). {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074121.
FT   VARIANT     153    153       I -> M (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs767890671).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074122.
FT   VARIANT     157    157       R -> Q (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs121434295).
FT                                {ECO:0000269|PubMed:25736335,
FT                                ECO:0000269|PubMed:7920641}.
FT                                /FTId=VAR_004320.
FT   VARIANT     175    175       A -> T (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074123.
FT   VARIANT     183    183       R -> Q (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs574132670).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074124.
FT   VARIANT     195    195       A -> V (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs760161369).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074125.
FT   VARIANT     196    196       G -> D (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204014).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074126.
FT   VARIANT     215    215       Missing (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity). {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074127.
FT   VARIANT     218    218       V -> L (in MTHFRD; decreased affinity for
FT                                FAD cofactor).
FT                                {ECO:0000269|PubMed:20236116}.
FT                                /FTId=VAR_074128.
FT   VARIANT     222    222       A -> V (common polymorphism; at
FT                                homozygosity reduces the risk for
FT                                colorectal cancer in individuals with
FT                                adequate folate status; decreased risk
FT                                for adult acute leukemia; increased risk
FT                                for NTDFS; thermolabile; decreased
FT                                affinity for FAD cofactor; 50% reduced
FT                                activity; dbSNP:rs1801133).
FT                                {ECO:0000269|PubMed:10536004,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:20236116,
FT                                ECO:0000269|PubMed:7647779,
FT                                ECO:0000269|PubMed:9545406,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_009528.
FT   VARIANT     225    225       I -> L (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs200100285).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074129.
FT   VARIANT     226    226       Missing (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074130.
FT   VARIANT     227    227       T -> M (in MTHFRD; dbSNP:rs748571395).
FT                                {ECO:0000269|PubMed:7726158}.
FT                                /FTId=VAR_004321.
FT   VARIANT     251    251       P -> L (in MTHFRD).
FT                                {ECO:0000269|PubMed:7726158}.
FT                                /FTId=VAR_004322.
FT   VARIANT     253    253       V -> F (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074131.
FT   VARIANT     254    254       P -> S (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs786204017).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074132.
FT   VARIANT     255    255       G -> V (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs786204018).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074133.
FT   VARIANT     256    256       I -> N (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs373398993).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074134.
FT   VARIANT     257    257       F -> V (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs786204019).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074135.
FT   VARIANT     323    323       L -> P (in MTHFRD; dbSNP:rs121434297).
FT                                {ECO:0000269|PubMed:8940272}.
FT                                /FTId=VAR_009531.
FT   VARIANT     324    324       N -> S (in MTHFRD; dbSNP:rs267606887).
FT                                {ECO:0000269|PubMed:9781030}.
FT                                /FTId=VAR_009532.
FT   VARIANT     325    325       R -> C (in MTHFRD; dbSNP:rs371085894).
FT                                {ECO:0000269|PubMed:7726158}.
FT                                /FTId=VAR_004323.
FT   VARIANT     335    335       R -> C (in MTHFRD; dbSNP:rs748289202).
FT                                {ECO:0000269|PubMed:7726158}.
FT                                /FTId=VAR_004324.
FT   VARIANT     335    335       R -> H (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; no effect on affinity for
FT                                NADPH; dbSNP:rs543016186).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074136.
FT   VARIANT     338    338       M -> T (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs368321176).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074137.
FT   VARIANT     339    339       W -> G (in MTHFRD; loss of
FT                                methylenetetrahydrofolate reductase
FT                                activity; dbSNP:rs267606886).
FT                                {ECO:0000269|PubMed:25736335,
FT                                ECO:0000269|PubMed:9781030}.
FT                                /FTId=VAR_009533.
FT   VARIANT     348    348       P -> S (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204021).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074138.
FT   VARIANT     354    354       H -> Y (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204022).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074139.
FT   VARIANT     357    357       R -> C (in MTHFRD; dbSNP:rs779993607).
FT                                {ECO:0000269|PubMed:7726158}.
FT                                /FTId=VAR_004325.
FT   VARIANT     363    363       R -> H (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204023).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074140.
FT   VARIANT     372    372       K -> E (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204024).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074141.
FT   VARIANT     377    377       R -> C (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs121434296).
FT                                {ECO:0000269|PubMed:25736335,
FT                                ECO:0000269|PubMed:8940272}.
FT                                /FTId=VAR_009534.
FT   VARIANT     377    377       R -> H (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs750323424).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074142.
FT   VARIANT     387    387       G -> D (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH).
FT                                {ECO:0000269|PubMed:10679944,
FT                                ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_009535.
FT   VARIANT     421    421       W -> S (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs200137991).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074143.
FT   VARIANT     422    422       G -> R (in dbSNP:rs45571736).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018857.
FT   VARIANT     429    429       E -> A (common polymorphism; decreased
FT                                risk for adult acute leukemia;
FT                                thermolabile; decreased activity;
FT                                dbSNP:rs1801131).
FT                                {ECO:0000269|PubMed:10536004,
FT                                ECO:0000269|PubMed:9545395,
FT                                ECO:0000269|PubMed:9719624,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014882.
FT   VARIANT     435    435       F -> S (in MTHFRD; dbSNP:rs754015864).
FT                                {ECO:0000269|PubMed:20236116}.
FT                                /FTId=VAR_074144.
FT   VARIANT     470    470       E -> A. {ECO:0000269|PubMed:18987736}.
FT                                /FTId=VAR_054158.
FT   VARIANT     506    506       Y -> D (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204026).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074145.
FT   VARIANT     519    519       R -> C (in dbSNP:rs45496998).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018858.
FT   VARIANT     519    519       R -> H (in dbSNP:rs45449298).
FT                                /FTId=VAR_050293.
FT   VARIANT     536    536       V -> F (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204028).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074146.
FT   VARIANT     566    566       G -> E (in dbSNP:rs2274974).
FT                                /FTId=VAR_050294.
FT   VARIANT     572    572       P -> L (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs144508139).
FT                                {ECO:0000269|PubMed:10679944,
FT                                ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_009536.
FT   VARIANT     574    574       V -> G (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH).
FT                                {ECO:0000269|PubMed:20236116,
FT                                ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074147.
FT   VARIANT     575    575       V -> G (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204031).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074148.
FT   VARIANT     586    586       E -> K (in MTHFRD).
FT                                {ECO:0000269|PubMed:10679944}.
FT                                /FTId=VAR_009537.
FT   VARIANT     594    594       R -> Q (in dbSNP:rs2274976).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018859.
FT   VARIANT     598    598       L -> P (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204034).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074149.
FT   VARIANT     628    628       L -> P (in MTHFRD; reduced
FT                                methylenetetrahydrofolate reductase
FT                                activity; reduced affinity for NADPH;
FT                                dbSNP:rs786204037).
FT                                {ECO:0000269|PubMed:25736335}.
FT                                /FTId=VAR_074150.
FT   VARIANT     653    653       T -> M (in dbSNP:rs35737219).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018860.
SQ   SEQUENCE   656 AA;  74597 MW;  F16E774833D054B8 CRC64;
     MVNEARGNSS LNPCLEGSAS SGSESSKDSS RCSTPGLDPE RHERLREKMR RRLESGDKWF
     SLEFFPPRTA EGAVNLISRF DRMAAGGPLY IDVTWHPAGD PGSDKETSSM MIASTAVNYC
     GLETILHMTC CRQRLEEITG HLHKAKQLGL KNIMALRGDP IGDQWEEEEG GFNYAVDLVK
     HIRSEFGDYF DICVAGYPKG HPEAGSFEAD LKHLKEKVSA GADFIITQLF FEADTFFRFV
     KACTDMGITC PIVPGIFPIQ GYHSLRQLVK LSKLEVPQEI KDVIEPIKDN DAAIRNYGIE
     LAVSLCQELL ASGLVPGLHF YTLNREMATT EVLKRLGMWT EDPRRPLPWA LSAHPKRREE
     DVRPIFWASR PKSYIYRTQE WDEFPNGRWG NSSSPAFGEL KDYYLFYLKS KSPKEELLKM
     WGEELTSEES VFEVFVLYLS GEPNRNGHKV TCLPWNDEPL AAETSLLKEE LLRVNRQGIL
     TINSQPNING KPSSDPIVGW GPSGGYVFQK AYLEFFTSRE TAEALLQVLK KYELRVNYHL
     VNVKGENITN APELQPNAVT WGIFPGREII QPTVVDPVSF MFWKDEAFAL WIERWGKLYE
     EESPSRTIIQ YIHDNYFLVN LVDNDFPLDN CLWQVVEDTL ELLNRPTQNA RETEAP
//
